As a computer guy, I'd say if the boards are hosted on virtual servers (which is likely -- y'know, the cloud 'n stuff), it's likely that the posts haven't propagated everywhere yet -- hence posts seem to disappear. Of course that's assuming no one is actually delete posts and the software is up to snuff.
A complicating factor seems to be CFP's share offering priced at 5.54. The N-2 filing was Apr 17. The only place you can find this info is CFP msg board or SEC site (CFP company id = 0001399186).
There's some sentiment that CRF and CLM pps will have a draw-down meanwhile.
I think we've generally understood that QE would eventually end. Then we have the knowledge of the "leak" of the Fed's March minutes. Now regulators have an itch to scratch. It seems everyone has been warned.
Doc - the Cornerstones looked interesting. The various pre and post ex's seemed to converge for possible entry thusly: CFP Wed-Fri, CRF Fri-Tues, and CLM Fri-Wed. I'd look for an exit probably Thurs-Fri 5/9-5/10.
My original posting of this disappeared. Anyway, SCD pays quarterly and historically averages 0.35 on the short trade. Either from X-17 to X-3 or from X+46 to X-3 (all on the open).
is a mid-cap with quarterly distributions. The short trades from X-17 to X-3 or from X+46 to X-3 (all on the open), has yielded $0.35 historically, based on data going back to Q1 2009.
First thought: does this replace QE3? No. 450B yen is 4.5B USD, which is about one-ninth of the monthly Fed MBS purchases.
Price appreciation works pretty easily in "up" markets, which is what we've had since the end of 2008.
Cyclical trading, as Doc et al. propose, should work in flat and up markets and possibly at times in down markets. In doing so, you are essentially attempting to capture a portion of the price appreciation component of any market.
It's plausible, though I can't guess the FDA's decision. This outlines my general approach for initial data mining.
1. wikipedia: Dihydroergotamine
It has similar actions to the triptans, acting as an agonist to the serotonin 5-HT(1D) receptors...
2. google books: The Cleveland Clinic Manual of Headache Therapy
Ergots, as with triptans, are contraindicated in vascular disease including peripheral vascular disease, coronary artery disease, and stroke. Ergots are contraindicated in pregnancy and carry an FDA pregnancy category X. They may cause retroperitoneal, valvular, and/or pulmonary fibrosis with prolonged daily use of 6 months. This is mediated through 5-HT(2B) action.
3. google: levadex 5ht2b
Research paper: Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy
Our results clearly show that DHE and for the first time 8′-OH-DHE act as agonists vs both 5-HT2B and 5-HT2CRs.